Affinia Therapeutics
PrivateLast Round
Series C
Oct 7, 2025
Est. Valuation
$145M
Total Funding Raised
$210M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Affinia Therapeutics is a biotechnology company that develops next-generation gene therapies using a proprietary platform to engineer novel adeno-associated virus vectors for the treatment of rare and prevalent diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Affinia Therapeutics Comparables
Compare Affinia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Solid Biosciences Inc. | 83% | |
| Nuevocor | 81% | |
| Capsida Biotherapeutics | 79% | |
Affinia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 7, 2025 | ||||
| Series B | May 3, 2021 | ||||
| Series A | Mar 31, 2020 |
Key People
Founding team and executive leadership
Affinia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| RA Capital Management | Series B |
| Farallon Capital Management | Series B |
| TCG Crossover | Series B |
| GV | Series C, Series B |
| Perceptive Advisors | Series C, Series B |
| New Enterprise Associates (NEA) | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
Presenting data on AFTX-201 program for bag3-associated DCM at upcoming conference.
- Apr 28, 2026
Presenting data at the American Society of Gene & Cell Therapy 2026 Annual Meeting.
Affinia Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Affinia Therapeutics's valuation, stock price, and market status.